| Literature DB >> 33276669 |
Mariusz Mital1, Kosma Szutkowski2, Karolina Bossak-Ahmad1, Piotr Skrobecki1, Simon C Drew1, Jarosław Poznański1, Igor Zhukov1, Tomasz Frączyk1, Wojciech Bal1.
Abstract
The Aβ4-42 peptide is a major beta-amyloid species in the human brain, forming toxic aggregates related to Alzheimer's Disease. It also strongly chelates Cu(II) at the N-terminal Phe-Arg-His ATCUN motif, as demonstrated in Aβ4-16 and Aβ4-9 model peptides. The resulting complex resists ROS generation and exchange processes and may help protect synapses from copper-related oxidative damage. Structural characterization of Cu(II)Aβ4-x complexes by NMR would help elucidate their biological function, but is precluded by Cu(II) paramagneticism. Instead we used an isostructural diamagnetic Pd(II)-Aβ4-16 complex as a model. To avoid a kinetic trapping of Pd(II) in an inappropriate transient structure, we designed an appropriate pH-dependent synthetic procedure for ATCUN Pd(II)Aβ4-16, controlled by CD, fluorescence and ESI-MS. Its assignments and structure at pH 6.5 were obtained by TOCSY, NOESY, ROESY, 1H-13C HSQC and 1H-15N HSQC NMR experiments, for natural abundance 13C and 15N isotopes, aided by corresponding experiments for Pd(II)-Phe-Arg-His. The square-planar Pd(II)-ATCUN coordination was confirmed, with the rest of the peptide mostly unstructured. The diffusion rates of Aβ4-16, Pd(II)-Aβ4-16 and their mixture determined using PGSE-NMR experiment suggested that the Pd(II) complex forms a supramolecular assembly with the apopeptide. These results confirm that Pd(II) substitution enables NMR studies of structural aspects of Cu(II)-Aβ complexes.Entities:
Keywords: 13C relaxation; ATCUN motif; Alzheimer’s disease; Aβ peptide; NMR spectroscopy; Palladium(II)
Year: 2020 PMID: 33276669 PMCID: PMC7731285 DOI: 10.3390/ijms21239200
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1The formation of the 1:1 Pd(II) complex of A monitored by CD. (A) The 40 h evolution of CD spectra of the sample containing 0.3 mM A and 0.255 mM at pH 4.0 and room temperature. (B) The six-hour evolution of CD spectra of the same sample after the change of pH to 6.5. (C) The time dependence of ellipticity at 360 and 321 nm.
Figure 2HPLC/MS characterization of products of the two-step procedure of obtaining the Pd(A) samples. (A) HPLC chromatogram of the sample containing initially 0.5 mM A and 0.425 mM KPdCl. (B) ESI-MS spectra of the respective HPLC peaks. (C) IMS characterization of A and Pd(A) species at pH 6.5.
Figure 3A Tyr10 fluorescence ( = 280 nm, = 303 nm) quenching by Cu(II) (red dots) and Pd(II) (blue circles). Regions corresponding to the binding of the first and second metal ion equivalents are marked by dashed lines. [A] = 25 M, [MES] = 20 mM, pH 6.5.
Figure 4Overlay of the 2D heteronuclear H-C HSQC NMR spectra recorded for (A) aliphatic and (B) aromatic regions for A peptide in apo (red) and Pd(II) saturated (blue) forms. The assignments and changes in the position of the resonances are shown. The experiments were performed on Varian Inova 500 NMR spectrometer.
Figure 5The 3D structure of Phe-Arg-His-amide (FRH) peptide represented the N-terminal ATCUN/NTS motif saturated with Pd(II) ion based on collected NMR constraints and crystallographic data available for GGH tripeptide [33].
Figure 6The 3D structure of Pd(A) complex included the N-terminal ATCUN/NTS motif binding the Pd(II) ion.
Figure 7Integral attenuation vs. gradient amplitude in PGSE NMR experiment for A and Pd(A) complex in solution. The A peptide (filled circles), equimolar Pd(A) complex 1:1 (open circles) and 1:1.4 (open squares). The experiments were performed on a Varian Inova 500 NMR spectrometer.